BioNetwork 2014 (past event)
27 - 29 October, 2014
Microsoft , Singapore, FL
The Ritz-Carlton, Laguna Niguel, CA
Day 2
06:30 - 08:00 Sunrise Jog
Join other runners to get your heart pumping and blood flowing before a full day of partnership and deal-making. Both your body and your pipeline will be healthy at BioNetwork. All levels/paces welcome.
08:00 - 08:45 Networking Breakfast
08:45 - 08:50 Welcoming Remarks
Sara Mueller, Executive Director, BioNetwork
08:50 - 09:00 Chairperson’s Opening Address
09:00 - 09:40 PANEL: Adapting Your Risk Tolerance And Decision-Making Behaviors In Response To Today’s Scientific And Deal-Making Landscape
Speakers:
Anne Altmeyer Executive Director of Business Development Novartis
Stefano Pieri Corporate Director, Licensing & Business Development Menarini IFR
Nouhad Husseini Director of Business Development Regeneron Pharmaceuticals, Inc.
Stephen E. Yoder, MD, MBA Global Lead, CV/Metabolic Search, Evaluation and Diligence Bristol-Myers Squibb
Cammie Edwards Associate Director, Strategic Alliances UCSF MMTI & Strategic Alliances
Anne Altmeyer Executive Director of Business Development Novartis
Stefano Pieri Corporate Director, Licensing & Business Development Menarini IFR
Nouhad Husseini Director of Business Development Regeneron Pharmaceuticals, Inc.
Stephen E. Yoder, MD, MBA Global Lead, CV/Metabolic Search, Evaluation and Diligence Bristol-Myers Squibb
Cammie Edwards Associate Director, Strategic Alliances UCSF MMTI & Strategic Alliances
• Exploring how the rapid pace of scientific innovation is impacting our industry
o Identifying the best ways to keep up and not be overwhelmed by the pace of scientific innovation
• Examining how biotech financing options have shifted over the past year
• Determining how companies need to adapt their risk tolerance and decision-making behaviors as a response to rapid scientific innovation and changes to biotech financing alternatives
• How have transactions become riskier and how can you minimize this risk?
Stephen E. Yoder, MD, MBA
Global Lead, CV/Metabolic Search, Evaluation and DiligenceBristol-Myers Squibb
09:40 - 09:55 Biotech Spotlight: Charleston Labs
09:55 - 10:10 Biotech Spotlight: Diasome Pharmaceuticals Inc.
10:10 - 10:50 PANEL: Innovative Financing And Deal Structures
•Exploring the current state of big pharma partnering—what are the recent trends?
•Examining option-based M&A deals—a win/win for investors and buyers?
•Discovering more innovative deal types and new ways to structure equity investments
10:50 - 11:25 Networking And Refreshment Break
11:25 - 12:05 PANEL: Determining How Health Economics And Pricing Reimbursement Are Impacting Research Outcomes And Partnering Strategy
• Examining the current state of pricing reimbursement globally; what are the differences among Europe, the US, and other areas you work in?
• Explaining why health outcomes research so important to your potential partners; Will it continue to be a major driver?
• Debating whether health economics and research outcomes need to be incorporated into clinical trials no later than phase 2, and perhaps even in phase 1
• Establishing how health economic and research outcome data either drive value or cripple your opportunity for partnering
Doug Jermasek
Senior Vice President, North America & Global MarketingIntercept Pharmaceuticals, Inc.
12:05 - 12:20 Biotech Spotlight: Istari Oncology
12:20 - 12:35 Biotech Spotlight: Vectron Biosolutions AS
12:35 - 13:45 Networking Luncheon
13:45 - 14:25 PANEL: Exploring Opportunities And Overcoming Challenges To Do Business In China And Other Emerging Markets
Speakers:
Paul Grayson President and Chief Executive Officer RuiYi
Kia Motesharei Head, Global Licensing & Business Development, Immunology EMD Serono / Merck KGaA
Vincent Liu Managing Director and Chief US Representative Fosun Pharma
John Gu President & Chief Scientific Officer Renascions Corporation
Moderator:
Wei Zhang Head, Corporate Development Good Start Genetics Inc.
Paul Grayson President and Chief Executive Officer RuiYi
Kia Motesharei Head, Global Licensing & Business Development, Immunology EMD Serono / Merck KGaA
Vincent Liu Managing Director and Chief US Representative Fosun Pharma
John Gu President & Chief Scientific Officer Renascions Corporation
Moderator:
Wei Zhang Head, Corporate Development Good Start Genetics Inc.
• Determining why there is a big appetite for acquiring companies and licensing in China; how does China factor into biopharma’s plans for the future?
• The Wild, Wild West: Developing a strategy to overcome issues in regulatory approval, reimbursement, and more
• Establishing which product profiles work in China and which do not
• Outlining successes, challenges, and lessons learned in working in China and other emerging markets
Kia Motesharei
Head, Global Licensing & Business Development, ImmunologyEMD Serono / Merck KGaA
14:25 - 14:40 Biotech Spotlight: Twister Biotech
14:40 - 15:20 PANEL: Identifying Steps To A Successful Integration Management – From Contracting To Implementation
Speakers:
Paola Casarosa Global Head Of Business Development and Licensing Respiratory Boehringer Ingelheim
Jeffrey Warmke Senior Vice President, External Scientific Affairs Daiichi Sankyo
Cammie Edwards Associate Director, Strategic Alliances UCSF MMTI & Strategic Alliances
Matthew Meyer Chief Business Officer CareDX
Paola Casarosa Global Head Of Business Development and Licensing Respiratory Boehringer Ingelheim
Jeffrey Warmke Senior Vice President, External Scientific Affairs Daiichi Sankyo
Cammie Edwards Associate Director, Strategic Alliances UCSF MMTI & Strategic Alliances
Matthew Meyer Chief Business Officer CareDX
• Ensuring both the buy and the sell side get what they want in an acquisition or other integration deal, from contracting to implementation
• Exploring the people puzzle: determining the right people to keep and creating an effective process for letting others go
• Keeping discovery and development programs underway and on track
• Blending or preserving cultures and overcoming corporate integration hurdles
Paola Casarosa
Global Head Of Business Development and Licensing RespiratoryBoehringer Ingelheim
Matthew Meyer
Chief Business OfficerCareDX
15:20 - 16:05 Networking & Refreshment Break
16:05 - 16:20 Biotech Spotlight: Cardiocell LLC
16:20 - 17:00 PANEL: Tackling Big Data And Real World Outcomes To Catalyze Further Growth In Your Pipeline
Speakers:
Wei Zhang Head, Corporate Development Good Start Genetics Inc.
John Mattison Assistant Medical Director Chief Medical Information Officer Kaiser Permanente
Jonathan Hirsch President and Founder Syapse
Moderator:
Cammie Edwards Associate Director, Strategic Alliances UCSF MMTI & Strategic Alliances
Wei Zhang Head, Corporate Development Good Start Genetics Inc.
John Mattison Assistant Medical Director Chief Medical Information Officer Kaiser Permanente
Jonathan Hirsch President and Founder Syapse
Moderator:
Cammie Edwards Associate Director, Strategic Alliances UCSF MMTI & Strategic Alliances
• Defining big data, real world outcomes, and real world data: which is the most actionable concept?
• With so much being logged and tracked electronically, how can real world data take processes and technology apart, then restructure them most efficiently?
• How can big data help us get more creative as to how we collaborate (even across industry verticals) to get to the actual solutions that patients and providers want
• Creating the right combination of people (prescribers and other healthcare institutions), processes, and technology to be successful using big data
John Mattison
Assistant Medical Director Chief Medical Information OfficerKaiser Permanente
